|Drug Name||GPCR-targeted Project 008|
A new generation antagonist bombesin analogue is being developed for the treatment of solid tumors. The drug candidate binds selectively and with high affinity to the GRP receptors expressed by several types of tumors and can be developed as radio-labeled therapeutic or diagnostic agent.
|Target||Gastrin releasing peptide receptor (GRPR)|
|Drug Modality||Small molecule|
|Product Category||New Molecular Entity|
|Mechanism of Action||GRPR antagonist|
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.